Chemoprevention of gastrointestinal cancer

Cancer and Metastasis Reviews

Volumn 16, Issue 3-4, 1997, Pages 405-419

  Montoya, Roselina G ^a   Wargovich, Michael J ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antioxidants; Antiproliferatives; Chemoprevention; Clinical trials; Colorectal cancer; Metabolism modulators

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CALCIUM SALT; EFLORNITHINE; FOLIC ACID; IBUPROFEN; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; ORGANOSULFUR DERIVATIVE; RETINOID; RETINOL; SELENIUM; SULINDAC; URSODEOXYCHOLIC ACID;

CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; COLON CARCINOGENESIS; DIETARY FIBER; DIGESTIVE SYSTEM CANCER; HUMAN; LOW FAT DIET; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030709207     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1005820831902     Document Type: Review

References (164)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. Ca Cancer J Clin 47: 5-27, 1997
2. Potter JD, Slattery ML, Bostick RM et al.: Colon cancer: A review of the epidemiology. Epidemiol Rev 15: 499-545, 1993
3. Potter JD: Colon cancer-do the nutritional epidemiology, the gut physiology and the molecular biology tell the same story? J Nutr 123: 418-423, 1993
4. Stenmetz KA, Potter JD: Vegetables, fruits, and cancer. I. Epidemiology. Cancer Causes Control 2: 325-357, 1991
5. Kelloff GJ, Boone CW, Steele VE et al.: Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials. Cancer Res 54: 2015s-2024s, 1994
6. Steele VE, Moon RC, Lubet RA et al.: Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: Methods and results from the NCI chemoprevention drug development program. J Cell Biochem 20: 32-54, 1994
7. Lipkin M: Gastrointestinal cancer: Pathogenesis, risk factors and the development of intermediate biomarkers for chemoprevention studies. J Cell Biochem (Suppl 16G): 1-13, 1992
8. Lipkin M: Application of intermediate biomarkers to studies of cancer prevention in the gastrointestinal tract: Introduction and perspective. Am J Clin Nutr 54: 188S-192S, 1991
9. Muto T, Bussey HJR, Morson BC: The evolution of cancer of the colon and rectum. Cancer 36: 2251-2270, 1975
10. O'Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz BG, Dickersin R, Ewing S, Geller S, Kasimian D, Komorowski R, Szporn A: The national polyp study: Determinants of high grade dysplasia in colorectal adenomas. Gastroenterology 98: 371-379, 1990
11. Chu DZ, Giacco G, Martin RG, Guinee VF: The significance of synchronous carcinoma and polyps in the colon and rectum. Cancer 57: 445-450, 1986
12. Shinya H, Wolff WI: Morphology, anatomic distribution and cancer potential of colonic polyps: An analysis of 7000 polyps endoscopically removed. Ann Surg 190: 679-683, 1979
13. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal tumour development. N Engl J Med 319: 525-532, 1988
14. Cannon Albright LA, Skolnick MH, Bishop DT, Lee RG, Burt RW: Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med 319: 533-537, 1988
15. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990
16. Cho KR, Vogelstein B: Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. J Cell Biochem 16 (Suppl G): 137-141, 1992
17. Su L-K, Vogelstein B, Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 262: 1734-1737, 1993
18. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D, Finniear R, Markham A, Groffen J, Boguski MS, Altschul SF, Horli A, Ando H, Miyoshi Y, Miki Y, Nishisho I, Nakamura Y: Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251: 1366-1370, 1991
19. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228: 187-190, 1985
20. El-Deiry WS, Nelkin BD, Celano P, Yen R-WC, Falco JP, Hamilton SR, Baylin SB: High expression of the DNA methyltransferase gene characerizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci USA 88: 3470-3474, 1991
21. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T: CpG Methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8: 1063-1067, 1993
22. Bhave MR, Wilson MJ, Poirier LA: c-H-Ras and c-K-ras gene hypomethylation in the livers and hepatomas of rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis 9: 343-348, 1988
23. Feinberg AP, Vogelstein B: Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 111: 47-54, 1983
24. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297, 1987
25. Khosravi-Far R, Der CJ: The ras signal transduction pathway. Cancer Met Rev 13: 67-89, 1994
26. Fearon ER, Cho KR, Nigro JM, Kern SE, Simmons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW: Identification of a chromosome 18q gene which is altered in colorectal cancers. Science 247: 49-56, 1990
27. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B: p53 Gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717-7722, 1990
28. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991
29. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J: Induction of apoptosis by wildtype p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89: 4495-4499, 1992
30. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-707, 1989
31. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R: Allelotype of colorectal carcinomas. Science 244: 207-211, 1989
32. Gentilini M, Duflo B, Richard-Lenoble D, Brucker G, Danis M, Niel G, Meunier Y: Assessment of RP35972 (oltipraz) a new antischistosomal drug against Schistosoma mematobium, Schistosoma mansoni, and Schistosome intercalatum. Acta Trop 37: 271-274, 1980
33. Trock B, Lanza E, Greenwald P: Dietary fiber, vegetables, and colon cancer: Critical review and metanalysis of the epidemiologic evidence. J Natl Cancer Inst 82: 650-661, 1990
34. National Research Council: Committee on Diet, Nutrition and Cancer. National Academy Press, Washington DC, 1982
35. Ansher SS, Dolan P, Bueding E: Biochemical effects of dithiolthiones. Food Chem Toxicol 24: 405-415, 1986
36. Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD: Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz) and related 1,2-dithiol-3-thione and 1,2-dithiol-3-ones. Cancer Res 47: 4271-4277, 1987
37. Davidson NC, Egner PA, Kensler TW: Transcriptional control of glutathione-s-transferase gene expression by the chemoprotective agent 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz) in rat liver. Cancer Res 50: 2251-2255, 1990
38. Rao CV, Rivenson A, Katiwalla M, Kelloff GJ, Reddy BS: Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res 53: 2502-2506, 1991
39. Wattenberg LW, Bueding E: Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz) on carcinogenesis induced by benzo(a)pyrene, diethylnitrosamine. and uracil mustard. Carcinogenesis 7: 1379-1381, 1986
40. Rao CV, Tokoma K, Kelloff G, Reddy BS: Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats. Carcinogenesis 12: 1051-1055, 1991
41. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC: Chemoprevention of OH-BBN induced bladder cancer in mice by oltipraz alone and in combination with 4-HPR and DFMO. Anticancer Res 14: 5-11, 1994
42. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Sigman CC: Chemopreventive drug development: Perspectives and progress. Cancer Epidem Biomarkers Prev 3: 85-98, 1994
43. Helmes CT, Becker RA, Seidenberg JM, Schindler JE, Kelloff GJ: Chemoprevention of mouse skin tumorigenesis by dietary oltipraz (Abstract). Proc Am Assoc Cancer Res 30: 177, 1989
44. Roebuck BD, Liu Y-L, Rogers AR, Groopman JD, Kensler TW: Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): Predictive role for short-term molecular dosimetry. Cancer Res 51: 5501-5506, 1991
45. Moon RC, Rao KVN, Detrisac CJ, Kelloff GJ, Steele VE, Doody LA: Chemoprevention ol respiratory tract neoplasia in the hamster by oltipraz, alone and in combination. Int J Oncol 4: 661-667, 1994
46. Clapper ML, Wood M, Leahy K, Lang D, Miknyoczki S, Ruggeri BA: Chemopreventive activity of oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters. Carcinogenesis 16: 2159-2165, 1995
47. LeRoy J-P, Barreau M, Cotrel C, Jeanmart C, Messer, Benazet F: Laboratory studies of 35 972 R.P., a new schistosomicidal compound. Proc Int Congr Chemother 1: 148-150, 1978
48. El-Bayoumy K: The role of selenium in cancer prevention. Cancer Prev 1: 15, 1991
49. Milner JA: Inhibition of chemical carcinogenesis and tumorigenesis by selenium. Adv Exp Med Biol 206: 449-163, 1986
50. Griffin AC: The role of selenium in the chemoprevention of cancer. Adv Cancer Res 29: 419-442, 1979
51. Ip C: The chemopreventive role of selenium in carcinogenesis. J Am Coll Toxicol 5: 7-20, 1986
52. Medina D: Mechanisms of selenium inhibition of tumorigenesis. J Am Coll Toxicol 5: 21-27, 1986
53. Fan AM, Kizer KW: Selenium: Nutritional, toxicological, and clinical aspects. West J Med 153: 160-167, 1990
54. Reddy BS, Sugie S, Maruyama H, El-Bayoumy K, Morra P: Chemoprevention of colon carcinogenesis by dietary organoselenium, benzylselenocyanate, in F344 rats. Cancer Res 47: 5901-5904, 1987
55. Reddy BS, Rivenson A, Kulkarni N, Upadhyaya P, El-Bayoumy K: Chemoprevention of colon carcinogenesis by the synthetic organoselenium compound 1,4-phenylenebis (methylene)selenocyanate. Cancer Res 52: 5635-5640, 1992
56. Nayini J, El-Bayoumy K, Sugie S, Cohen LA, Reddy BS: Chemoprevention of experimental mammary carcinogenesis by the synthetic organoselenium compound benzylselencyanate, in rats. Carcinogenesis 10: 509-512, 1989
57. Glynn SA, Albanes D: Folate and cancer: A review of the literature. Nutr Cancer 22: 101-119, 1994
58. Eto I, Krumdieck CL: Role of vitamin B12 and folate deficiencies in carcinogenesis. Adv Exp Med Biol 206: 313-330, 1986
59. Cravo ML, Mason JB, Dayal Y, Hutchinson M, Smith D, Selhub J, Rosenberg IH: Folate deficiency enhances the development of colonic neoplasia in dimethylhydrazine treated rats. Cancer Res 52: 5002-5006, 1992
60. Cravo M, Mason JB, Salomon RN: Folate deficiency in rats causes hypomethylation of liver DNA (Abstract). Gastroenterology 100: A356, 1991
61. Balaghi M, Wagner C: DNA methylation in folate deficiency, use of CpG methylase. Biochem Biophys Res Comm 193: 1184-1190, 1993
62. Armstrong B, Doll R: Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15: 617-631, 1975
63. Lewisohn R, Leuchtenberger C, Leuchtenberger R, Keresztesy JC: The influence of liver L. casei factor on spontaneous breast cancer in mice. Science 104: 436-437, 1946
64. Baggott JE, Vaughn WH, Juliana MM, Eto I, Krumdieck CL, Grubbs CJ: Effects of folate deficiency and supplementation on methylnitrosourea-induced rat mammary tumors. J Natl Cancer Inst 84: 1740-1744, 1992
65. Machlin LJ, Bendich A: Free radical tissue damage: Protective role of antioxidant nutrients. FASEB J 1: 441-445, 1987
66. Dorgan JF, Schatzkin A: Antioxidants micronutrients in cancer prevention. Hematol Oncol Clin North Am 5: 43-68, 1991
67. Tannebaum SR, Wishnok JS: Inhibition of nitrosamine formation by ascorbic acid. Ann NY Acad Sci 498: 354-363, 1987
68. Newberne PM, Locniskar M: Roles of micronutrients in cancer prevention: Recent evidence from the laboratory. Prog Clin Biol Res 346: 119-134, 1990
69. Block G: Epidemiological evidence regarding vitamin C and cancer. Am J Clin Nutr 54: 1310s-1314s. 1991
70. Woutersen RA, van Garderon-Hoetmer A: Inhibition of dietary fat-promoted development of (pre)neoplastic lesions in exocrine pancreas of rats and hamsters by supplemental vitamins A, C, and E. Cancer Lett 41: 179-189, 1988
71. Ramesha A, Rao N, Rao AR, Jannu LN, Hussain SP: Chemoprevention of 7,12-demethylbenz(a)anthracene-induced mammary carcinogenesis in rat by the combined actions of selenium, magnesium, ascorbic acid and retinyl acetate. Jpn J Cancer Res 81: 1239-1246, 1990
72. Pauling L: Effect of ascorbic acid on incidence of spontaneous mammary tumors and UV-light-induced skin tumorigenesis in mice. Am J Clin Nutr 54: 1252s-1255s, 1991
73. Liehr JG: Vitamin C reduces the incidence and severity of renal tumors induced by estradiol or diethyl stilbestrol. Am J Clin Nutr 54: 1256s-1260s, 1991
74. Dorgan JF, Schatzkin A: Antioxidant micronutrients in cancer prevention. Hematol Oncol Clin North Am 5: 43-68, 1991
75. Machlin LJ, Bendich A: Free radical tissue damage: Protective role of antioxidant nutrients. FASEB J 1: 441-445, 1987
76. McCay PB, King MM: Vitamin E: Its role as a biologic free radical scavenger and its relationship to the microsomal mixed-function oxidase system. In: Machlin LJ (ed) Vitamin E-A Comprehensive Treatise. Marcel Dekker, Inc. New York, 1980, pp 289-317
77. Shklar G, Schwartz J: Tumor necrosis factor in experimental cancer regression with alpha-tocopherol, beta-carotene, canthaxanthin, and algae extract. Eur J Cancer 24: 839-850, 1988
78. Prasad KN, Edwards-Prasad J: Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. Cancer Res 42: 550-555, 1982
79. Bertram JS, Kolonel LN, Meyskens FL: Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 47: 3012-3031, 1987
80. Fiala ES, Reddy BS, Weisburger JH: Naturally occurring anticarcinogenic substances in foodstuffs. Annu Rev Nutr 5: 295-321, 1985
81. Weerapradist W, Shklar G: Vitamin E inhibition of hamster buccal pouch carcinogenesis. A gross, histologic, and ultrastructural study. Oral Surg Oral Med Oral Pathol 54: 304-312, 1982
82. Shklar G: Oral mucosal carcinogenesis in hamsters: Inhibition by vitamin E. J Natl Cancer Inst 68: 791-797, 1982
83. Shamberger RJ, Rudolph G: Protection against cocarcinogenesis by antioxidants. Experientia 22: 116, 1966
84. Odeleye OE, Eskelson CD, Mufti SI, Watson RR: Vitamin E protection against nitrosamine-induced esophageal tumor incidence in mice immunocompromised by retroviral infection. Carcinogenesis 13: 1811-1816, 1992
85. Cook MG, McNamara P: Effect of dietary vitamin E on dimethyl-hydrazine-induced colonic tumors in mice. Cancer Res 40: 1329-1331, 1980
86. Thompson HJ: Effects of combined deficiencies of selenium (Se) and vitamin E (VIT E) on the initiation and promotion phases of 7,12-dimethyl-benz(a)anthracene (DMBA)-induced mammary tumorigenesis (Abstract). Proc Am Assoc Cancer Res 32: 146, A 877, 1991
87. Nyandieka HS, Wakhis J, Kilonzo MM: Association of reduction of AFB1-induced liver tumours by antioxidants with increased activity of microsomal enzymes. Indian J Med Res 92: 332-336, 1990
88. Hasegawa R, Furukawa F, Toyoda K, Takahashi M, Hayashi Y, Hirose M, Ito N: Inhibitory effects of antioxidants in N-bis(2-hydroxypropyl)nitrosamine-induced lung carcinogenesis in rats. Jpn J Cancer Res 81: 871-877, 1990
89. Hill DL, Grubbs CJ: Retinoids and cancer prevention. Annu Rev Nutr 12: 161-181, 1992
90. Lotan R: Cellular biology of the retinoids. In: Degos L, Parkinson PR (eds) Retinoids in Oncology. Springer, Berlin, 1995, pp 27-42
91. Lotan R: Retinoids and apoptosis: Implications for cancer chemoprevention and therapy. J Natl Cancer Inst 87: 1655-1657, 1995
92. Lotan R: Cell invasion as a target for chemoprevention. In: Steele VE, Stoner GD, Boone CW, Kelloff GJ (eds) Cellular and Molecular Targets for Chemoprevention. CRC Press, Inc, Boca Raton. 1992, pp 339-348
93. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK: Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Eng J Med 322: 1405-1410, 1995
94. Giguere V, Ong ES, Segui P, Evans RM: Identification of a receptor for the morphogen-retinoic acid. Nature 330: 625-625, 1987
95. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM: Nuclear receptor that identifies a novel retinoic acid response pathway. Nature 345: 224-229, 1990
96. Leid M, Kastner P, Chambon P: Multiplicity generates diversity in the retinoic acid pathway. Trends Biol Sci 17: 427-433, 1992
97. Sporn MB, Roberts AB: Interactions of retinoids and transforming growth factor-β in regulation of cell differentiation and proliferation. Mol Endocrinol 5: 3-7, 1991
98. Lotan R, Nicolson GL: Inhibitory effects of retinoic acid or retinyl acetate on the growth of untransformed, transformed, and tumor cells in vitro. J Natl Cancer Inst 59: 1717-1722, 1977
99. Jones-Villeneuve EM, McBurney MW, Rogers KA, Kalnins VI: Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells. J Cell Biol 94: 253-262, 1982
100. Moon RC, Mehta RG, Rao KJVN: Retinoids and cancer in experimental animals. In: Sporn MB, Roberts AB, Goodman DS (eds) The Retinoids. Raven Press, New York, 1994, pp 573-595
101. Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M: Inhibition of aberrant crypt growth by non-steroidal antiinflammatory agents and differentiating agents in the rat colon. Int J Cancer 60: 515-519, 1995
102. Lipkin M, Newmark HL, Kelloff G: Calcium, Vitamin D, and Prevention of Colon Cancer. CRC Press, Boca Raton, 1991
103. Steinbach G, Morotomi M, Nomoto K, Lupton J, Weinstein IB, Holt PR: Calcium reduces the increased fecal 1,2-sn-diacylglycerol content in intestinal bypass patients: A possible mechanism for altering colonic hyperproliferation. Cancer Res 54: 1216-1219, 1994
104. Lipkin M, Newmark H: Calcium and colon cancer. Nutr Rev 51: 213-214, 1993
105. Lans JI, Jaszewski R, Arlow FI, Tureaud J, Luk GO, Majumdar AP: Supplemental calcium suppresses colonic mucosal ornithine decarboxylase activity in elderly patients with adenomatous polyps. Cancer Res 51: 3416-3419, 1991
106. Wargovich MJ, Eng WVS, Newmark HL, Bruce WR: Calcium ameliorates the toxic effect of deoxycholic acid on colonic epithelium. Carcinogenesis 4: 1205-1207, 1983
107. Wargovich MJ, Eng VWS, Newmark HI: Calcium inhibits the damaging and compensatory proliferative effects of fatty acids on mouse colon epithelium. Cancer Lett 23: 253-258, 1984
108. Wargovich MJ, Baer A: Basic and clinical investigations of dietary calcium in the prevention of colorectal cancer. Prev Med 18: 672-679, 1989
109. Sweeb RK, Beijnen JH: Signal transduction pathways. New targets in oncology. Pharm World Sci 15: 233-242, 1993
110. Berridge MD: The biology and medicine of calcium signalling. Mol Cell Endocrinol 98: 119-124, 1994
111. Whitfield JF, Bird RP, Chakravarthy BR, Isaacs RJ, Morley P: Calcium-cell cycle regulator, differentiator, killer, chemopreventor, and maybe, tumor promoter. J Cell Biochem (Suppl) 22: 74-91, 1995
112. Lipkin M, Newmark H: Calcium and the prevention of colon cancer. J Cell Biochem (Suppl) 22: 65-73, 1995
113. Pegg AE, McGovern KA, Weist L: Decarboxylation of α-defluoromethylornithine by ornithine decarboxylase. Biochem J 241: 305-307, 1987
114. Luk GO, Casero RA: Polyamines in normal and cancer cells. Adv Enzyme Regul 26: 91-105, 1987
115. Pegg AE: Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res 48: 759-774, 1988
116. Pendyala L, Creaven PJ, Porter CW: Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a Phase I chemoprevention clinical trial. Cancer Epidem Biomarkers Prev 2: 235-241, 1993
117. Homma Y, Kakizoe T, Samma S, Oyasu R: Inhibition of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis by α-difluoromethylornithine. Cancer Res 47: 6176-6179, 1987
118. Ratko TA, Detrisac CJ, Rao KVN, Thomas CF, Kelloff GJ, Moon RC: Interspecies analysis of the chemopreventive efficacy of dietary α-difluoromethylornithine. Anticancer Res 10: 67-72, 1990
119. Moon RC, Detrisac CJ, Thomas CF, Kelloff GJ: Chemoprevention of experimental bladder cancer. J Cell Biochem 161 (Suppl): 134-138, 1992
120. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D-L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50: 2562-2568, 1990
121. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS: Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16-α-fluoro-s-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 51: 4528-4534, 1991
122. Nigro ND, Bull AW, Boyd ME: Importance of the duration of inhibition on intestinal carcinogenesis by difluoromethylornithine in rats. Cancer Lett 35: 153-158, 1987
123. Thompson HJ, Herbst EJ, Meeker LD, Minocha R, Ronan AM, Fite R: Effect of D,L-α-difluoromethylornithine on murine mammary carcinogenesis. Carcinogenesis 5: 1649-1651, 1984
124. Thompson HJ, Meeker LD, Herbst EJ, Ronan AM, Minocha R: Effect of concentration of D,L-2-difluoromethylornithine on murine mammary carcinogenesis. Cancer Res 45: 1170-1173, 1985
125. Thompson HJ, Ronan AM, Ritacco KA, Meeker LD: Effect of tamoxifen and D,L-2-difluoromethylornithine on the growth, ornithine decarboxylase activity and polyamine content of mammary carcinomas induced by 1-methyl-1-nitrosourea. Carcinogenesis 7: 837-840, 1986
126. Thompson HJ, Ronan AM: Effect of D,L-2-difluoromethylornithine and endocrine manipulation on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis 7: 2003-2006, 1986
127. Moore MA, Tsuda H, Ogiso T, Mera Y, Ito N: Enhancement of phenotypic instability by α-difluoromethylornithine and butylated hydroxyanisole in rapidly induced rat liver lesions. Cancer Lett 25: 145-151, 1984
128. Lehnert T, Buhl K, Ivankovic S: Inhibition of gastric tumorigenesis by α-difluoromethylornithine in rats treated with N-methyl-N'-nitro-N-nitrosoguanidine. J Cancer Res Clin Oncol 119: 594-598, 1993
129. Weeks CE, Herrmann AL, Nelson FR, Slaga TJ: α-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci USA 79: 6028-6032, 1982
130. Takigawa M, Verma AK, Simsiman RC, Boutwell RK: Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by α-difluoromethylornithine. Cancer Res 43: 3732-3738, 1983
131. Verna AK, Duvick L, Ali M: Modulation of mouse skin tumor promotion by dietary 13-cis-retinoic acid and α-difluoromethylornithine. Carcinogenesis 7: 1019-1023, 1986
132. Hixson LJ, Garewal HS, McGee D, Sloan D, Fennerty MB, Sampliner RE, Gerner EW: Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidem Biomark Prev 2: 369-374, 1993
133. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 231: 232-235, 1971
134. Earnest DL, Hixson LJ, Alberts DS: Piroxicam and other cyclooxygenase inhibitors: Potential for cancer chemoprevention. J Cell Biochem (Suppl) 161: 156-166, 1992
135. Kelloff GJ, Malone WF, Boone CW, Sigman CC, Fay JR: Progress in applied chemoprevention research. Semin Oncol 17: 438-455, 1990
136. Kudo T, Narisawa T, Abo S: Antitumor activity of indomethacin on methylazoxymethanol-induced large bowl tumors in rats. Gann 71: 260-264, 1980
137. Pollard M, Luckert PH: Effect of piroxicam on primary intestinal tumors induced in rats by N-methyl-nitrosourea. Cancer Lett 25: 117-121, 1984
138. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ: A protective effect of sulindac against chemically induced primary colonic tumors in mice. J Path 156: 341-347, 1988
139. Reddy BS, Rao CV, Rivenson A, Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colonic carcinogenesis in F344 rats. Carcinogenesis 14: 1493-1497, 1993
140. Boone CW, Steele VE, Kelloff GJ: Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutat Res 267: 251-255, 1992
141. Boone CW, Kelloff GJ, Steele VE: The natural history of intraepithelial neoplasia: Relevance to the search for intermediate endpoint biomarkers. J Cell Biochem 16G: 23-26, 1992
142. Alberts DS, Ritenbaugh C, Story JA et al.: A randomized, double blind, placebo-controlled study of the effect of wheat bran fiber and calcium on fecal bile acids in patients with resected adenomatous colon polyps. J Natl Cancer Inst 88 (2): 81-92, 1996
143. Schatzkin A, Dorgan J, Swanson C et al.: Diet and cancer: Future etiologic research (Review). Env Health Perspect 103 (Suppl) 8: 171-175, 1995
144. Schatzkin A, Kelloff G: Chemo-and dietary prevention of colorectal cancer. Eur J Cancer 31A: 1198-1204, 1995
145. Alberts DS, Einspahr J, Reese-McGee S et al.: Effects of dietary fiber on epithelial cell proliferation in patients with resected colon cancer. J Natl Cancer Inst 82: 1280-1285, 1990
146. Baron JA, Greenberg ER: Could aspirin really prevent colon cancer? N Engl J Med 325: 1644-1646, 1991
147. Baron JA, Wargovich MJ, Tosteson TD et al.: Epidemiological use of rectal proliferation indices. Cancer Epi Biomarkers & Prev 4: 57-63, 1995
148. Baron JA, Tosteson TD, Wargovich MJ et al.: Calcium supplementation and rectal mucosal proliferation: A randomized controlled trial. J Natl Cancer Inst 87: 1303-1307, 1995
149. Greenberg ER, Baron JA, Tosteson TD et al.: A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study. New Engl J Med 331: 141-147, 1994
150. Meyskens FL Jr, Gerner EW: Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer. J Cell Biochem (Suppl) 22: 126-131, 1995
151. Meyskens FL Jr, Emerson SS, Pelot D et al.: Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 86: 1122-1130, 1994
152. Love RR, Carbone PP, Verma AK et al.: Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst 85: 732-737, 1993
153. Giovannucci E, Stampfer MJ, Colditz GA et al.: Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 85: 875-884, 1993
154. Freudenheim JL, Graham S, Marshall JR et al.: Folate intake and carcinogenesis of the colon and rectum. Int J Epidemiol 20: 368-374, 1991
155. Wali RK, Frawley BP Jr, Hartmann S et al.: Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: Potential roles of protein kinase C-alpha, -beta II, and -zeta. Cancer Res 55: 5257-5264, 1995
156. Earnest DL, Holubec H, Wali RK et al.: Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 54: 5071-5074, 1994
157. Clark LC, Combs GF, Turnbull BW et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin, a randomized controlled trial. JAMA 276: 1957-1963, 1996
158. Clark LC, Hixson LJ, Combs GF Jr et al.: Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps. Cancer Epi Biomarkers & Prev 2: 41-46, 1993
159. Heath CW Jr, Thun MJ, Greenberg ER et al.: Nonsteroidal antiinflammatory drugs and human cancer. Report of an interdisciplinary research workshop. Cancer 74: 2885-2888, 1994
160. Rigau J, Pique JM, Rubio E et al.: Effects of long-term sulindac therapy on colonic polyposis. Ann Int Med 115: 952-955, 1995
161. Labayle D, Fischer D, Vielh Pet al.: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterol 101: 635-639, 1991
162. Alberts DS, Hixson L, Ahnen D et al.: Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem (Suppl) 22: 18-23, 1995
163. Earnest DL, Hixson LJ, Alberts DS: Piroxicam and other cyclooxygenase inhibitors: Potential for cancer chemoprevention. J Cell Biochem (Suppl) 161: 156-166, 1992
164. Earnest DL, Hixson LJ, Finley PR et al.: Arachidonic acid cascade inhibitors in chemoprevention of human colon cancer: Preliminary studies. In: Wattenberg LW, Lipkin M, Boone CW (eds) Cancer Chemoprevention. Boca Raton, CRC Press, 1992, pp 165-180